Because of its heterogeneity, lack of prognostic markers, tumor-escape mechanisms, and frequent relapse upon surgical intervention, treatment of hepatocellular carcinoma (HCC) remains challenging. In this issue of Clinical Cancer Research, Groß and colleagues characterize a rodent model that might help identify novel drugs for combinatorial sorafenib-based therapies for HCC. Clin Cancer Res; 21(19); 1–3. ©2015 AACR.
See related article by Groß et al., p. 4440
- Received June 11, 2015.
- Accepted June 15, 2015.
- ©2015 American Association for Cancer Research.